Background: It is thought that Lass4 may be either a bona fide (dihydro)ceramide synthase or a modulator of its activity. When overexpressed in cells is involved in the production of sphingolipids containing different fatty acid donnors (N-linked stearoyl- (C18) or arachidoyl- (C20) ceramides) in a fumonisin B1-independent manner.
Positive Control: Lung and embryo.
Purification Method: Antigen Immunoaffiinity Purification.
Source: Rabbits were immunized with a synthetic peptide derived from human Lass4 protein.
Formulation: Provided as solution in phosphate buffered saline with 0.08% sodium azide.
References: 1. Min, J., et al. '(Dihydro)ceramide synthase 1 regulated sensitivity to cisplatin is associated with the activation of p38 mitogen-activated protein kinase and is abrogated by sphingosine kinase 1.' Mol. Cancer Res. 2007, 5(8):801-812
2. Ruckhaberle, E., et al. 'Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer.' Breast Cancer Res Treat. 2007 Dec 4 [Epub ahead of print].
UniProt: Q9HA82.
Caution: This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals.
English
Deutsch
